Navigation Links
MCG to conduct first FDA-approved stem cell trial in pediatric cerebral palsy

AUGUSTA, Ga. Medical College of Georgia researchers are conducting the first FDA-approved clinical trial to determine whether an infusion of stem cells from umbilical cord blood can improve the quality of life for children with cerebral palsy.

The study will include 40 children age 2-12 whose parents have stored cord blood at the Cord Blood Registry in Tucson, Ariz.

Umbilical cord blood is rich in stem cells, which can divide and morph into different types of cells throughout the body, said Dr. James Carroll, professor and chief of pediatric neurology in MCG School of Medicine and principal investigator on the study.

Cerebral palsy, caused by a brain injury or lack of oxygen in the brain before birth or during the first few years of life, can impair movement, learning, hearing, vision and cognitive skills. Two to 3 children in 1,000 are affected by it, according to the Centers for Disease Control.

Animal studies indicate that infused stem cells help injured brain cells recover and replace brain cells that have died, Dr. Carroll said.

"Autologous stem cell transplantation, in which the transplant recipient is also the donor, is the safest form of stem cell transplantation because it carries virtually no threat of immune system rejection," he said.

While no controlled clinical trials have been conducted to date, previous studies have shown marked improvement in children with cerebral palsy about three months after an initial infusion of cord blood.

"Evidence up to this point has been purely anecdotal," Dr. Carroll said. "While a variety of cord blood stem cell therapies have been used successfully for more than 20 years, this study is breaking new ground in advancing therapies for brain injury a condition for which there is currently no cure."

Children will begin the study with a neurological exam by MCG pediatric neurologists Elizabeth Sekul and Nicole Brockway. Then, half of the study participants will receive an infusion of their own cord blood while the other half receive a placebo. Three months later, the children will be evaluated without physicians knowing which group received the stem cell infusion. Afterward, children who didn't get the cord blood initially will receive an infusion. Children will return three and six months later for evaluation.

Researchers will periodically assess the children's motor skills and neurological development.

"For the purposes of this study, we're not looking at stem cells as a possible cure; rather whether stem cells can help change the course of these types of brain injuries in children," Dr. Carroll said.


Contact: Jennifer Hilliard
Medical College of Georgia

Related medicine news :

1. Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Childrens Hospital
2. World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins
3. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
4. CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
5. NIH awards more than $54 Million to Kaiser Permanente to conduct health research
6. HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo
7. Swanson Health Products' Vitamin E and Acai Dietary Supplements Pass Quality Control Tests Conducted by
8. China Sky One Medical, Inc. to Present at Rodman & Renshaw Annual Global Investment Conference and Conduct Non-Deal Roadshow in the U.S.
9. Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement
10. China Sky One Medical, Inc. to Conduct Non-Deal Roadshow in Hong Kong and Singapore
11. iCRco Conducts 2009 Asia/Pacific Distributor Training Program
Post Your Comments:
Related Image:
MCG to conduct first FDA-approved stem cell trial in pediatric cerebral palsy
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
(Date:11/30/2015)... ... 30, 2015 , ... The presidential race normally deals with political issues of ... a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? ... than anyone wants to admit when it comes to how people are viewed by ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one ... , Their study showed that small molecule analogs that target the functions of ...
(Date:11/30/2015)... ... 30, 2015 , ... Dr. Seth D. Margulies specializes in orthodontics and is ... Margulies to experience the best available orthodontic experience in the area. Dr. Margulies ... , Orthodontics is the branch of dentistry that specializes in the diagnosis, prevention, and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith ... Sensium Healthcare, a global pioneer in wireless monitoring ... Boston, MA , Mr. Smith will ... Sensium,s global commercial strategy.  He will also directly ... to build clinical evidence for SensiumVitals, the first ...
Breaking Medicine Technology: